Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

ABSTRACT:

Unlabelled

Background

Targeted therapies in renal cell carcinoma can have different effects on primary and metastatic tumors. To pave the way for predictive biomarker development, we assessed differences in expression of targets of currently approved drugs in matched primary and metastatic specimens from 34 patients.

Methods

Four cores from each site were embedded in tissue microarray blocks. Expression of B-Raf, C-Raf, cKIT, FGF-R1, HIF-2α, mTOR, PDGF-Rβ, VEGF-R1, VEGF-R2, VEGF-R3, VEGF, VEGF-B, VEGF-C, VEGF-D, MEK1, and ERK1/2 was studied using a quantitative immunofluorescence method.

Results

No significant differences were observed in global expression levels in primary and metastatic renal cell carcinoma tumors, with the exception of MEK, which had higher

SUBMITTER: Aziz SA 

PROVIDER: S-EPMC3575219 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature